Effects of Antidepressants on Sexual Functioning
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00051259|
Recruitment Status : Completed
First Posted : January 8, 2003
Last Update Posted : October 4, 2010
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder (MDD)||Drug: Extended-Release Bupropion Hydrochloride||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||420 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||June 2004|
|Actual Study Completion Date :||June 2004|
- Percentage of subjects with orgasm dysfunction. Change in HAMD-17 total score.
- Percent of subjects in remission, HAMD-17. Changes in Sexual Functioning Questionnaire. Percent of responders, HAMD-17 CGI-I and CGI-S.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051259
Show 23 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|